Evidence map›Paper›PMID 26184377›Full record

Observational studyAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2015

Hypomagnesemia and Mortality in Incident Hemodialysis Patients.

Lin Li, Elani Streja, Connie M Rhee, Rajnish Mehrotra, Melissa Soohoo, Steven M Brunelli, Csaba P Kovesdy, Kamyar Kalantar-Zadeh

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Magnesium to prevent kidney disease-associated vascular calcification: crystal clear?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Lin LiHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, CA.
Elani StrejaHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, CA.
Connie M RheeHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, CA.
Rajnish MehrotraKidney Research Institute, Division of Nephrology, University of Washington, Seattle, WA.
Melissa SoohooHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, CA.
Steven M BrunelliDaVita Clinical Research, Minneapolis, MN.
Csaba P KovesdyDivision of Nephrology, Memphis Veterans Affairs Medical Center, Memphis, TN.
Kamyar Kalantar-ZadehHarold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, CA. Electronic address: kkz@uci.edu.
University of California, Irvine · USDaVita Clinical Research (United States) · USMemphis VA Medical Center · USUniversity of California, Irvine Medical Center · USUniversity of Washington · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
MALNUTRITION, DIET AND RACIAL DISPARITIES IN CKDK24DK091419 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI KALANTAR-ZADEH, KAMYAR · 2011 to 2020
$1.8M
Examining Racial and Cardiovascular Paradoxes in Chronic Kidney DiseaseR01DK078106 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALANTAR-ZADEH, KAMYAR · 2007 to 2011
$1.1M
Comparative Effectiveness of Dialysis ModalitiesR01DK095668 · NIDDK · UNIVERSITY OF WASHINGTON · PI KALANTAR-ZADEH, KAMYAR, MEHROTRA, RAJNISH · 2012 to 2014
$1.0M
Hypothyroidism, Cardiovascular Health, and Survival in Kidney DiseaseK23DK102903 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI RHEE, CONNIE MEEYOUNG · 2014 to 2018
$955k
NCATS NIH HHS UL1 TR001414NIDDK NIH HHS K23 DK102903NIDDK NIH HHS K23-DK102903NIDDK NIH HHS K24 DK091419NIDDK NIH HHS K24-DK091419NIDDK NIH HHS R01 DK078106NIDDK NIH HHS R01 DK095668NIDDK NIH HHS R01-DK095668
6 · The paper itself

Abstract

backgroundIn the general population, low serum magnesium levels are associated with poor outcomes and death. While limited data suggest that low baseline magnesium levels may be associated with higher mortality in hemodialysis (HD) patients, the impact of changes in magnesium levels over time is unknown. STUDY

designWe examined the association of time-varying serum magnesium levels with all-cause mortality using multivariable time-varying survival models adjusted for clinical characteristics and other time-varying laboratory measures. SETTING &

participants9,359 maintenance HD patients treated in a large dialysis organization between 2007 and 2011. PREDICTOR: Time-varying serum magnesium levels across 5 magnesium increments (<1.8, 1.8-<2.0, 2.0-<2.2, 2.2-<2.4, and ≥2.4mg/dL). OUTCOME: All-cause mortality.

results2,636 individuals died over 5 years. Time-varying serum magnesium levels < 2.0mg/dL were associated with higher mortality after adjustment for demographics and comorbid conditions, including hypertension, diabetes, and malignancies (reference: magnesium, 2.2-<2.4mg/dL): adjusted HRs for serum magnesium level < 1.8 and 1.8 to <2.0mg/dL were 1.39 (95% CI, 1.23-1.58; P<0.001) and 1.20 (95% CI, 1.06-1.36; P=0.004), respectively. Some associations were attenuated to the null after incremental adjustment for laboratory test results, particularly serum albumin. However, among patients with serum albumin measurements, low albumin level (<3.5g/dL) and magnesium level < 2.0mg/dL were associated with an additional death risk (adjusted HR, 1.17; 95% CI, 1.05-1.31; P=0.004), whereas patients with high serum albumin levels (≥3.5g/dL) exhibited low death risk (adjusted HRs of 0.53 and 0.53 [P≤0.001] for magnesium < 2.0 and ≥2.0mg/dL, respectively; reference: albumin < 3.5g/dL and magnesium ≥ 2.0mg/dL). LIMITATIONS: Causality cannot be determined, and residual confounding cannot be excluded given the observational study design.

conclusionsLower serum magnesium levels are associated with higher mortality in HD patients, including those with hypoalbuminemia. Interventional studies are warranted to examine whether correction of hypomagnesemia ameliorates adverse outcomes in this population.

Indexed as

AgedBiomarkersFemaleHumansIncidenceKidney Failure, ChronicMagnesiumMaleMiddle AgedMortalityRenal DialysisRetrospective StudiesBiomarkersMagnesiumall-cause mortalitycohortdeath riskdialysisend-stage renal disease (ESRD)hypomagnesemiaincident hemodialysis patientsMagnesiumserum albumintime-varying serum magnesium

Identifiers

PMID26184377
PMCPMC4658300
OpenAlexW917079217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.